
The Medicines Company Acquires Targanta

2009-02-27

WilmerHale client, The Medicines Company, announced yesterday that it had completed its acquisition of Targanta Therapeutics Corporation.

The Medicines Company completed the transaction through a cash tender offer followed by a short form merger. The Medicines Company paid Targanta stockholders \$2.00 per share, net to the seller in cash, plus the contractual right to receive up to an additional \$4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.

With the consummation of the acquisition, Targanta has become a wholly owned subsidiary of The Medicines Company. Further details can be found by clicking [here](#).

WilmerHale was legal advisor to The Medicines Company in this transaction, with a team including: partners [David Redlick](#), [Hal Leibowitz](#), [Stuart Falber](#) and [Jeffrey Hermanson](#); counsels [Marisa Murtagh](#) and [Jessica Lopez](#); and associates Dana Krueger and [Erica Koenig](#).